IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v11y2020i1d10.1038_s41467-020-18751-8.html
   My bibliography  Save this article

Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism

Author

Listed:
  • Elizabeth A. Killion

    (Amgen Research, Department of Cardiometabolic Disorders, Amgen Inc., One Amgen Center Dr)

  • Michelle Chen

    (Amgen Research, Department of Cardiometabolic Disorders, Amgen Inc., One Amgen Center Dr)

  • James R. Falsey

    (Amgen Research, Department of Selection and Modality Engineering, Amgen Inc., One Amgen Center Dr)

  • Glenn Sivits

    (Amgen Research, Department of Cardiometabolic Disorders, Amgen Inc., One Amgen Center Dr)

  • Todd Hager

    (Amgen Research, Department of Translational Safety & Bioanalytical Sciences, Amgen Inc., One Amgen Center Dr)

  • Larissa Atangan

    (Amgen Research, Department of Cardiometabolic Disorders, Amgen Inc., One Amgen Center Dr)

  • Joan Helmering

    (Amgen Research, Department of Cardiometabolic Disorders, Amgen Inc., One Amgen Center Dr)

  • Jae Lee

    (Amgen Research, Department of Cardiometabolic Disorders, Amgen Inc., One Amgen Center Dr)

  • Hongyan Li

    (Amgen Research, Department of Translational Safety & Bioanalytical Sciences, Amgen Inc., One Amgen Center Dr)

  • Bin Wu

    (Amgen Research, Department of Selection and Modality Engineering, Amgen Inc., One Amgen Center Dr)

  • Yuan Cheng

    (Amgen Research, Department of Selection and Modality Engineering, Amgen Inc., One Amgen Center Dr)

  • Murielle M. Véniant

    (Amgen Research, Department of Cardiometabolic Disorders, Amgen Inc., One Amgen Center Dr)

  • David J. Lloyd

    (Amgen Research, Department of Cardiometabolic Disorders, Amgen Inc., One Amgen Center Dr)

Abstract

Antagonism or agonism of the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) prevents weight gain and leads to dramatic weight loss in combination with glucagon-like peptide-1 receptor agonists in preclinical models. Based on the genetic evidence supporting GIPR antagonism, we previously developed a mouse anti-murine GIPR antibody (muGIPR-Ab) that protected diet-induced obese (DIO) mice against body weight gain and improved multiple metabolic parameters. This work reconciles the similar preclinical body weight effects of GIPR antagonists and agonists in vivo, and here we show that chronic GIPR agonism desensitizes GIPR activity in primary adipocytes, both differentiated in vitro and adipose tissue in vivo, and functions like a GIPR antagonist. Additionally, GIPR activity in adipocytes is partially responsible for muGIPR-Ab to prevent weight gain in DIO mice, demonstrating a role of adipocyte GIPR in the regulation of adiposity in vivo.

Suggested Citation

  • Elizabeth A. Killion & Michelle Chen & James R. Falsey & Glenn Sivits & Todd Hager & Larissa Atangan & Joan Helmering & Jae Lee & Hongyan Li & Bin Wu & Yuan Cheng & Murielle M. Véniant & David J. Lloy, 2020. "Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism," Nature Communications, Nature, vol. 11(1), pages 1-17, December.
    • Handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18751-8
    DOI: 10.1038/s41467-020-18751-8
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-020-18751-8
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-020-18751-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Stephen E. Flaherty & Olivier Bezy & Wei Zheng & Dong Yan & Xiangping Li & Srinath Jagarlapudi & Bina Albuquerque & Ryan M. Esquejo & Matthew Peloquin & Meriem Semache & Arturo Mancini & Liya Kang & D, 2023. "Chronic UCN2 treatment desensitizes CRHR2 and improves insulin sensitivity," Nature Communications, Nature, vol. 14(1), pages 1-16, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18751-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.